ATE414152T1 - Muteine von ifn-beta - Google Patents

Muteine von ifn-beta

Info

Publication number
ATE414152T1
ATE414152T1 AT95914045T AT95914045T ATE414152T1 AT E414152 T1 ATE414152 T1 AT E414152T1 AT 95914045 T AT95914045 T AT 95914045T AT 95914045 T AT95914045 T AT 95914045T AT E414152 T1 ATE414152 T1 AT E414152T1
Authority
AT
Austria
Prior art keywords
ifn
beta
muteins
those
recombinant dna
Prior art date
Application number
AT95914045T
Other languages
English (en)
Inventor
Susan E Goelz
Richard L Cate
E Pingchang Chow
R Blake Pepinsky
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE414152T1 publication Critical patent/ATE414152T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Amplifiers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
AT95914045T 1994-03-15 1995-03-13 Muteine von ifn-beta ATE414152T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/213,448 US5545723A (en) 1994-03-15 1994-03-15 Muteins of IFN-β

Publications (1)

Publication Number Publication Date
ATE414152T1 true ATE414152T1 (de) 2008-11-15

Family

ID=22795174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914045T ATE414152T1 (de) 1994-03-15 1995-03-13 Muteine von ifn-beta

Country Status (12)

Country Link
US (2) US5545723A (de)
EP (1) EP0750668B1 (de)
JP (2) JP3822903B2 (de)
AT (1) ATE414152T1 (de)
AU (1) AU695208B2 (de)
CA (1) CA2185352C (de)
DE (1) DE69535883D1 (de)
DK (1) DK0750668T3 (de)
FI (1) FI120356B (de)
NO (1) NO318989B1 (de)
NZ (2) NZ283217A (de)
WO (1) WO1995025170A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
AU766190B2 (en) 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
EP1366075B1 (de) 2001-02-27 2009-05-27 Maxygen Aps Neue interferon-beta-ähnliche moleküle
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
CA2463935A1 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
EP2292273A3 (de) 2001-10-10 2011-11-23 BioGeneriX AG Remodellierung und Glycokonjugation von Peptiden
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
AU2003277088A1 (en) * 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
UY29544A1 (es) * 2005-05-19 2006-12-29 Schering Ag Tratamiento de enfermedades usando un sistema mejorado de expresión regulada
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
DOP2006000117A (es) * 2005-05-19 2007-11-30 Schering Ag Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
US20080219952A1 (en) * 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
WO2008134406A1 (en) * 2007-04-25 2008-11-06 The Board Of Trustees Of The Leland Stanford Junior University Ischemia-induced neovascularization is enhanced by hcns-sc transplantation
CN101675071B (zh) * 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
EP2207890A4 (de) * 2007-10-05 2010-12-15 Barofold Inc Hochdruckbehandlung aggregierter interferone
CN102325878A (zh) 2008-12-23 2012-01-18 斯特姆塞尔思加利福尼亚有限公司 少突胶质前体细胞的靶向细胞群及制备与使用方法
WO2019073315A1 (en) 2017-10-09 2019-04-18 Mansour Poorebrahim ANALOGUE PEPTIDE OF INTERFERON-BETA

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK170476B1 (da) * 1980-04-03 1995-09-11 Biogen Inc Rekombinant DNA-molekyle, uni-cellulær vært transformeret med mindst ét rekombinant DNA-molekyle, fremgangsmåde til transformering af en uni-cellulær vært, samt fremgangsmåder til fremstilling af et polpeptid, der udviser den immunologiske eller biologiske aktivitet af human beta-interferon
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
EP0260350B1 (de) * 1986-09-05 1992-02-12 Cetus Oncology Corporation Oxidationsresistente Muteine von beta-Interferon, deren Herstellung und diese Muteine enthaltende Präparate
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL92124A (en) * 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
WO1993015609A1 (en) * 1992-02-05 1993-08-19 Thomas Jefferson University Interferon gene therapy for the treatment of vascular disorders

Also Published As

Publication number Publication date
DE69535883D1 (de) 2008-12-24
FI963630A0 (fi) 1996-09-13
US6127332A (en) 2000-10-03
EP0750668A1 (de) 1997-01-02
MX9604073A (es) 1997-12-31
CA2185352C (en) 2005-02-22
NO963837L (no) 1996-11-14
JP3822903B2 (ja) 2006-09-20
NO318989B1 (no) 2005-05-30
WO1995025170A1 (en) 1995-09-21
US5545723A (en) 1996-08-13
AU2120295A (en) 1995-10-03
DK0750668T3 (da) 2009-03-02
NO963837D0 (no) 1996-09-13
NZ283217A (en) 1998-05-27
AU695208B2 (en) 1998-08-06
JP2006199711A (ja) 2006-08-03
NZ329970A (en) 2000-01-28
JPH10500563A (ja) 1998-01-20
FI120356B (fi) 2009-09-30
CA2185352A1 (en) 1995-09-21
FI963630A7 (fi) 1996-09-13
EP0750668B1 (de) 2008-11-12

Similar Documents

Publication Publication Date Title
DE69535883D1 (de) Muteine von ifn-beta
DK305885A (da) Tumornecrosefaktor og derivater og mutantformer deraf, frem. til frems. deraf, frem. til isolering deraf fra en blanding med andre proteiner,praeparater deraf, dna som koder derfor, dna'en inkorporeret i en replicerbar vektor og celle transformeret dermed
RU95115239A (ru) Аналог эритропоэтина
HUT77575A (hu) Rekombináns adenovírus vektor és eljárás alkalmazására
NO931141L (no) Tnf-muteiner
DK0880970T3 (da) Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose
EP0787802A3 (de)
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
WO2002074980A3 (en) Muteins of hypoxia inducible factor alpha and methods of use thereof
WO1995025170B1 (en) NOVEL MUTEINS OF IFN-$g(b)
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE69024104D1 (de) Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase
ATE141946T1 (de) Hiv-2-virusvarianten
EP0592566A4 (de) Cysteinfreie il-6 mutanten.
PT817851E (pt) Dna codificador do virus do papiloma humano tipo 18
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
ATE76579T1 (de) Interferon-zusammensetzungen.
ATE100717T1 (de) Intralaesionale behandlung von basalzellenkarzinoma mittels rekombinanten humanen alpha-interferons.
DE59208025D1 (de) Neue thrombininhibitorische proteine aus landblutegeln
DE68918399D1 (de) Lymphokine, DNS-Sequenzen, die diese Lymphokine kodieren, und sie enthaltende pharmazeutische Zusammensetzungen.
SG128403A1 (en) Tnf-receptors, tnf binding proteins and dnas coding for them
DK103891A (da) Intralaesional behandling af pladeepitelcarcinoma med rekombinant human alfainterferon
IT1262545B (it) Sistema di espressione per linee cellulari eucariotiche
GR3025841T3 (en) An anti-hiv protein, tap 29, from trichosanthes, dna coding therefor and therapeutic uses thereof
ATE386803T1 (de) Intrazelluläre glukocortikoid-induzierte leucin- zipper modulatoren von mechanismen des apoptotischen zelltodes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties